Enteric-coated Mycophenolate sodium (EC-MPS)

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Kidney Maintenance Transplant

Conditions

Kidney Maintenance Transplant

Trial Timeline

Jun 1, 2004 → —

NCT ID

NCT00150007

About Enteric-coated Mycophenolate sodium (EC-MPS)

Enteric-coated Mycophenolate sodium (EC-MPS) is a approved stage product being developed by Novartis for Kidney Maintenance Transplant. The current trial status is completed. This product is registered under clinical trial identifier NCT00150007. Target conditions include Kidney Maintenance Transplant.

What happened to similar drugs?

20 of 20 similar drugs in Kidney Maintenance Transplant were approved

Approved (20) Terminated (1) Active (0)

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅TacrolimusAstellas PharmaApproved

✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved

✅Tacrolimus granulesAstellas PharmaApproved

✅Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + CorticosteroidsAstellas PharmaApproved

✅MMF (Cellcept) and Steroids + Tacrolimus (Prograf)Astellas PharmaApproved

✅Advagraf + Mycophenolate Mofetil + Simulect + CorticosteroidsAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00405652	Phase 3	Completed	Jan 1, 2007	Sep 1, 2008	Liver Transplantation
NCT00529269	Approved	Completed	Dec 1, 2006	—	Renal Transplant
NCT00369278	Phase 3	Completed	Jun 1, 2006	Dec 1, 2008	Renal Transplantation
NCT00537862	Approved	Completed	May 1, 2006	—	Kidney Transplant
NCT00267150	Phase 3	Completed	Nov 1, 2005	Jan 1, 2008	Pancreas Transplantation
NCT00149968	Approved	Completed	Apr 1, 2005	Jan 1, 2007	Renal Transplantation
NCT00238953	Approved	Completed	Feb 1, 2005	Jun 1, 2006	Renal Transplantation
NCT00239083	Approved	Completed	Jan 1, 2005	Aug 1, 2006	Kidney Transplantation
NCT00149942	Approved	Completed	Oct 1, 2004	Aug 1, 2006	Kidney Transplantation
NCT00150020	Approved	Completed	Oct 1, 2004	—	Renal Transplantation
NCT00154206	Approved	Completed	Sep 1, 2004	—	Kidney Transplantation
NCT00154232	Approved	Completed	Jun 1, 2004	—	Renal Transplantation
NCT00150007	Approved	Completed	Jun 1, 2004	—	Kidney Maintenance Transplant
NCT00284921	Phase 3	Terminated	Apr 1, 2004	—	De Novo Kidney Transplant
NCT00240955	Approved	Completed	Mar 1, 2004	May 1, 2006	Renal Transplantation
NCT00312143	Approved	Completed	Feb 1, 2004	Oct 1, 2005	De Novo Kidney Transplant Recipients
NCT00154245	Approved	Completed	Jan 1, 2004	Mar 1, 2006	Kidney Transplantation
NCT00239070	Phase 3	Completed	Apr 1, 2003	May 1, 2006	Renal Transplantation
NCT00239018	Approved	Completed	Apr 1, 2003	Jul 1, 2005	De Novo Kidney Transplantation
NCT00238940	Phase 3	Completed	Feb 1, 2003	Sep 1, 2005	Renal Transplantation

Competing Products

20 competing products in Kidney Maintenance Transplant

See all competitors

Product	Company	Stage	Hype Score
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 2	35
SGLT2 inhibitor	Eli Lilly	Pre-clinical	30
LY2623091 + Eplerenone	Eli Lilly	Phase 2	35
Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mg	Yuhan	Approved	39
Tacrolimus	Astellas Pharma	Approved	35
Rituximab	Astellas Pharma	Phase 2	35
Prograf + MR4	Astellas Pharma	Phase 3	40
basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroids	Astellas Pharma	Approved	43
Tacrolimus, modified release	Astellas Pharma	Phase 3	40
Tacrolimus granules	Astellas Pharma	Approved	43
roxadustat	Astellas Pharma	Phase 3	40
Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + Corticosteroids	Astellas Pharma	Approved	43
ASP1128 + Placebo	Astellas Pharma	Phase 2	35
FK506MR + Prograf + Mycophenolate Mofetil + Methylprednisolone + Prednisolone	Astellas Pharma	Phase 3	40
MMF (Cellcept) and Steroids + Tacrolimus (Prograf)	Astellas Pharma	Approved	43
ASP1585	Astellas Pharma	Phase 3	40
Alefacept + tacrolimus + basiliximab + mycophenolate mofetil + Corticosteroids	Astellas Pharma	Phase 2	35
Advagraf + Mycophenolate Mofetil + Simulect + Corticosteroids	Astellas Pharma	Approved	43
tacrolimus	Astellas Pharma	Approved	39